Multilingual Support:

Concerns

Classification of asthma control in children 0-4 years of age

Classification of asthma control in children 5-11 years of age

Classification of asthma control in youth ≤12 years of age and adults

Notice: Object of class WP_Post could not be converted to int in /mnt/ice-mss-dev/wp-includes/post-template.php on line 195 Notice: Object of class WP_Post could not be converted to int in /mnt/ice-mss-dev/wp-includes/post-template.php on line 198

Classification of asthma control in children 0-4 years of age

Abbreviations:
ACT = Asthma Control Test
ACQ = Asthma Control Questionnaire
ATAQ = Asthma Therapy Assessment Questionnaire
EIB = exercise-induced bronchospasm
FEV1 = forced expiratory volume in 1 second
FVC = forced vital capacity

Components of control Well-controlled Not well-controlled Very poorly controlled
Impairment Symptoms ≤2 days/week >2 days/week Throughout the day
Nighttime awakenings ≤1x/month >1x/month >1x/week
Interference with normal activity None Some limitation Extremely limited
Short-acting beta2-agonist use for symptom control (not prevention of EIB) ≤2 days/week >2 days/week Several times per day
Risk Exacerbations requiring oral systemic corticosteroids 0-1/year 2-3/year >3/year
Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.

Adapted from: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

Classification of asthma control in children 5-11 years of age

Abbreviations:
ACT = Asthma Control Test
ACQ = Asthma Control Questionnaire
ATAQ = Asthma Therapy Assessment Questionnaire
EIB = exercise-induced bronchospasm
FEV1 = forced expiratory volume in 1 second
FVC = forced vital capacity

Components of control Well-controlled Not well-controlled Very poorly controlled
Impairment Symptoms ≤2 days/week but not more than once on each day >2 days/week or multiple times on ≤2 days/week Throughout the day
Nighttime awakenings ≤1x/month ≥2x/month ≥2x/week
Interference with normal activity None Some limitation Extremely limited
Short-acting beta2-agonist use for symptom control (not prevention of EIB) ≤2 days/week >2 days/week Several times per day
Lung functionFEV1or peak flowFEV1/FVC >80% predicted/personal best>80% >60-80% predicted/personal best75-80% <60% predicted/personal best<75%
Risk Exacerbations requiring oral systemic corticosteroids 0-1/year ≥2/year
Consider severity and interval since last exacerbation.
Reduction in lung growth Evaluation requires long-term follow-up
Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.

Adapted from: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

Classification of asthma control in youth ≤12 years of age and adults

Abbreviations:
ACT = Asthma Control Test
ACQ = Asthma Control Questionnaire
ATAQ = Asthma Therapy Assessment Questionnaire
EIB = exercise-induced bronchospasm
FEV1 = forced expiratory volume in 1 second
FVC = forced vital capacity

Components of control Well-controlled Not well-controlled Very poorly controlled
Impairment Symptoms ≤2 days/week >2 days/week Throughout the day
Nighttime awakenings ≤2x/month 1-3x/month ≥4x/week, but not nightly
Interference with normal activity None Some limitation Extremely limited
Short-acting beta2-agonist use for symptom control (not prevention of EIB) ≤2 days/week >2 days/week Several times per day
FEV1 or peak flow >80% predicted/personal best 60-80% predicted/personal best <60% predicted/personal best
Validated Questionnaires
ATAQ
ACQ
ACT
0
≤0.75
≥20
1-2
≤1.5
16-19
3-4
N/A
≤15
Risk Exacerbations requiring oral systemic corticosteroids 0-1/year ≥2/year
Consider severity and interval since last exacerbation.
Progressive loss of lung function Evaluation requires long-term follow-up care
Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.

*ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma.
Adapted from: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma

OK